APLS

Apellis Pharmaceuticals Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↑ 8/10
  • Value↓ 3/10
Apellis Pharmaceuticals sales and earnings growth
APLS Growth
Good
  • Revenue Y/Y↑ 28.46%
  • EPS Y/Y↑ 111.25%
  • FCF Y/Y↑ 151.00%
Apellis Pharmaceuticals gross and profit margin trends
APLS Profitability
Good
  • Gross margin ↑ 89.80%
  • EPS margin↓ 2.20%
  • ROIC 5Y↓ -106.05%
Apellis Pharmaceuticals net debt vs free cash flow
APLS Risk
Good
  • Debt / Equity↓ 1.3
  • Debt / FCF↓ 0.1
  • Interest coverage↓ 1.5

Apellis Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Good risk rating.

More Biotechnology stocks ↗